The Carlyle Group LP (Nasdaq: CG) has agreed to buy pharmacy benefit manager WelDyneRx. The PE firm is making the investment out of the $13 billion Carlyle Partners VI U.S. buyout fund. Financial terms were not disclosed.
The acquisition comes as employers and patients face soaring health care costs. PBM’s are playing an increasingly larger role in negotiating plans between employers and insurers. Lakeland, Florida-based WellDyneRX provides prescription drug management between patients and providers through retail and specialty pharmacies. WellDyne RX serves employers, unions and providers. “We strive as a firm to invest in companies that improve accessibility and affordability of health care,” says Carlyle global health care head Stephen Wise.